9:03 AM
 | 
Jan 04, 2019
 |  BC Week In Review  |  Financial News  |  Completed Offerings

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008.

Boyu Capital and FountainVest led the round, with participation by Celgene Corp. (NASDAQ:CELG), WuXi Corporate Venture Fund, Taikang and existing...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >